The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.42
Bid: 17.42
Ask: 18.08
Change: 0.14 (0.80%)
Spread: 0.66 (3.789%)
Open: 17.42
High: 17.42
Low: 17.42
Prev. Close: 17.61
NANO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of GM, Move to Main Market and Placing

22 Apr 2015 16:45

RNS Number : 0446L
Nanoco Group PLC
22 April 2015
 

 

For immediate release

22 April 2015

 

 

 

NANOCO GROUP PLC

("Nanoco" or the "Company")

 

Result of General Meeting, Move to Main Market

and Placing to raise £20 million gross

 

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots and other nanomaterials, announces that all resolutions were duly passed at its General Meeting held earlier today in connection with the Company's proposed move from AIM to the Main Market of the London Stock Exchange and the Placing announced on 31 March 2015.

 

Following the outcome of the General Meeting, the Company will now proceed with the proposed move to the Main Market and the Placing to raise gross proceeds of £20 million.

A summary of the votes cast on the Resolutions put to Shareholders at the General Meeting is shown below:

 

Resolutions

For

Against

Withheld

Number

%

Number

%

Number

1

THAT, conditionally upon Admission, the New Articles of Association (as defined in the Circular) be approved and adopted as the new articles of association of the Company in substitution for, and to the exclusion of, the existing articles of association of the Company.

 

140,776,175

 

99.95

72,957

0.05

578

2

THAT, conditionally upon the passing of Resolution 1 and in addition to the authority conferred on the Directors at the annual general meeting of the Company held on 11 December 2014, the Directors be generally and unconditionally authorised, in accordance with section 551 of the Companies Act 2006, to allot up to 19,047,619 Ordinary Shares in aggregate in the capital of the Company, such authority to expire at the end of 31 July 2015.

 

140,776,753

 

99.94

80,400

0.06

0

3

THAT, conditionally upon the passing of Resolutions 1 and 2 and in addition to the authority conferred on the Directors at the annual general meeting of the Company held on 11 December 2014, the Directors be given power to allot up to 19,047,619 Ordinary Shares for cash pursuant to the authority referred to in Resolution 2 other than on a pro-rata basis to shareholders as if section 561 of the Companies Act 2006 did not apply, such authority to expire at the end of 31 July 2015.

 

140,761,553

 

99.86

 

201,664

0.14

15,200

 

The issued share capital of the Company on the date of the meeting was 217,330,383 ordinary shares of 10 pence each ("Ordinary Shares").

In accordance with the Disclosure Rules and Transparency Rules, a copy of the Resolutions proposed and passed at the General Meeting will be submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/NSM and will also be available for inspection at www.nanocotechnologies.com.

Notification of the Company's intention to de-list from AIM has been submitted to the London Stock Exchange. It is expected that the last day of dealings in the Ordinary Shares on AIM will occur on 30 April 2015.

Applications will shortly be made to the Official List and to the London Stock Exchange for 236,378,002 Ordinary Shares, fully paid and conditional upon Admission, to be admitted to listing on the premium segment of the Official List and to be admitted to trading on the Main Market. It is expected that Admission of the 236,378,002 Ordinary Shares will occur at 8.00 a.m. on 1 May 2015.

Completion of the Placing and Admission remains subject to certain conditions. A further announcement will be made in due course.

All capitalised terms in this announcement have the meaning given to them in the Circular, unless otherwise defined herein.

 

 

For further information, please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Mark Sullivan, Interim Chief Financial Officer

Canaccord Genuity - Nomad, Sponsor and Joint Broker

Tel: +44 (0) 20 7523 8000

Simon Bridges

Cameron Duncan

Mark Whitmore

Liberum - Joint Broker

Tel: +44 (0) 20 3100 2000

Simon Atkinson

Richard Bootle

Buchanan

Tel: +44 (0) 20 7466 5000

Mark Court / Sophie Cowles / Stephanie Watson

 

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and production of cadmium-free quantum dots and other nanomaterials for use in multiple applications including LCD displays, lighting, solar cells and bio-imaging. In the display market, it has an exclusive manufacturing and marketing licensing agreement with The Dow Chemical Company.

 

Nanoco was founded in 2001 and is headquartered in Manchester, UK. It has production facilities in Runcorn, UK, and a US subsidiary, Nanoco Inc, based in Concord, MA. Nanoco also has business development executives in Japan, Korea and Taiwan. Its technology is protected worldwide by a large and growing patent estate.

 

Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO. For further information please visit: www.nanocotechnologies.com.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCUUOVRVKASUAR
Date   Source Headline
2nd Aug 20237:00 amRNSISS recommendation to support Nanoco’s Board
1st Aug 20237:13 amRNSTotal Voting Rights
28th Jul 20235:23 pmRNSDirector/PDMR Shareholding
25th Jul 20232:55 pmRNSPublication of Shareholder Presentation
25th Jul 202312:52 pmRNSNanoco Group Plc
24th Jul 20237:00 amRNSHigh Court Confirmation of Capital Reduction
20th Jul 20237:00 amRNSNotification of Investor Presentation
18th Jul 20237:00 amRNSPosting of Circular and Notice of General Meeting
7th Jul 202311:23 amRNSGeneral Meeting - Voting Results
28th Jun 20237:00 amRNSReceipt of General Meeting Requisition Notice
20th Jun 20237:00 amRNSPosting of Circular and Notice of General Meeting
9th Jun 20237:00 amRNSBlocklisting Six-Monthly Return
19th May 20231:00 pmRNSResponse to Shareholder Letter
21st Apr 20236:00 pmRNSHolding(s) in Company
30th Mar 202311:46 amRNSHolding(s) in Company
28th Mar 20237:00 amRNSInterim Results
27th Mar 20231:19 pmRNSResponse to Shareholder Letter
23rd Mar 20238:40 amRNSNotice of Results
9th Mar 20233:11 pmRNSHolding(s) in Company
9th Feb 20237:00 amRNSDirector/PDMR Shareholding
7th Feb 20237:00 amRNSHolding(s) in Company
3rd Feb 20237:15 amRNSTrading Update
3rd Feb 20237:15 amRNSLitigation Settlement Update
18th Jan 202311:35 amRNSHolding(s) in Company
16th Jan 202312:45 pmRNSHolding(s) in Company
11th Jan 20232:40 pmRNSHolding(s) in Company
10th Jan 20232:37 pmRNSHolding(s) in Company
9th Jan 20237:00 amRNSLitigation Settlement Update
6th Jan 20237:00 amRNSLitigation Outcome – Settlement Agreed
4th Jan 20233:31 pmRNSHolding(s) in Company
20th Dec 20223:51 pmRNSHolding(s) in Company
20th Dec 20222:59 pmRNSResult of AGM
20th Dec 20227:00 amRNSAGM Statement
13th Dec 20227:00 amRNSBlock listing Six-monthly Return
9th Dec 20227:00 amRNSLitigation Update - Firm Trial Date
14th Nov 202210:46 amRNS2022 Annual Report and Notice of AGM
7th Nov 20224:13 pmRNSHolding(s) in Company
27th Oct 20225:19 pmRNSDirector/PDMR Shareholding
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.